Moxifloxacin vs Ciprofloxacin Otic Solution, — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Fluoroquinolone Antibacterial

Moxifloxacin

Brand: Moxifloxacin

First FDA approval: 2003-05-07

Fluoroquinolone Antibacterial

Ciprofloxacin Otic Solution,

First FDA approval: 2024-11-15

Lowest NADACAcquisition cost floor across all NDCs

$1.73Per unit

$6.93Per unit

Average NADACAcross all dosage forms and strengths

$3.33Up to $31.77

$6.93Up to $6.93

Generic manufacturersActive ANDA holders — FDA Orange Book

2021 total ANDAs filed

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$41.8MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

1.7M1.1M beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$25Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

34Minimal friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes20 manufacturers

NoBrand-only